Entasis Therapeutics (NASDAQ:ETTX – Get Rating) announced its quarterly earnings results on Wednesday. The company reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.09), MarketWatch Earnings reports.
Shares of ETTX stock traded up $0.04 during trading on Thursday, hitting $1.90. The company had a trading volume of 18,054 shares, compared to its average volume of 220,362. The firm has a market capitalization of $90.92 million, a P/E ratio of -1.74 and a beta of 1.60. The stock’s 50-day moving average price is $1.83 and its 200 day moving average price is $2.17. Entasis Therapeutics has a one year low of $1.40 and a one year high of $3.88.
A number of brokerages have recently issued reports on ETTX. Zacks Investment Research cut Entasis Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, March 10th. HC Wainwright cut Entasis Therapeutics from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $6.00 to $1.80 in a report on Friday, March 4th. Alliance Global Partners cut Entasis Therapeutics from a “buy” rating to a “neutral” rating in a report on Wednesday, March 16th. Finally, Wedbush cut Entasis Therapeutics from an “outperform” rating to a “neutral” rating and reduced their price objective for the stock from $9.00 to $1.80 in a report on Tuesday, March 8th. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $3.15.
Entasis Therapeutics Company Profile (Get Rating)
Entasis Therapeutics Holdings Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii.
- Get a free copy of the StockNews.com research report on Entasis Therapeutics (ETTX)
- There’s An Institutional Floor In Keurig Dr. Pepper
- Ford Falls Despite Optimistic Outlook
- Harley-Davidson Skids Into A Buying Opportunity
- Facebook (NASDAQ: FB) Soars And Wall Street Delights
- Automatic Data Processing Is Ready To Scale New Heights
Receive News & Ratings for Entasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.